Compare CVGI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | BDTX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 171.9M |
| IPO Year | 2004 | 2020 |
| Metric | CVGI | BDTX |
|---|---|---|
| Price | $5.08 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 676.2K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.18 | 130.71 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $755,231,000.00 | N/A |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $126.50 | ★ N/A |
| Revenue Growth | ★ 14.06 | N/A |
| 52 Week Low | $1.29 | $1.60 |
| 52 Week High | $5.88 | $4.94 |
| Indicator | CVGI | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 45.09 |
| Support Level | $4.69 | $1.60 |
| Resistance Level | $5.23 | $2.30 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 81.41 | 40.65 |
Commercial Vehicle Group Inc and its subsidiaries are a globalised provider of systems, assemblies, and components to international commercial vehicle markets and electric vehicle markets. It delivers real solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities it serves. The company has its manufacturing operations in the United States, Mexico, China, the United Kingdom, the Czech Republic, Ukraine, Morocco, Thailand, India, and Australia. Organisations' products are mainly sold in North America, Europe, and the Asia-Pacific region. It has three segments: Global Seating Segment, Global Electrical systmem, and Trim Systems and Components Segment, with the majority of revenue from Global Seating Segment.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.